Pipeline Report: January 2021 | Articles

Neoadjuvant Tavokinogene Telseplasmid Plus Nivolumab Under Evaluation in Advanced Melanoma

February 17th 2021

The first patient with operable, locally or regionally advanced melanoma has been dosed with the intratumoral DNA plasmid-based interleukin-12 therapy tavokinogene telseplasmid in combination with nivolumab as a neoadjuvant treatment before surgery in the investigator-initiated, phase 2 OMS-104 trial.

Zotiraciclib Plus Temozolomide Shows Meaningful Efficacy in Recurrent High-Grade Gliomas

February 5th 2021

February 5, 2021 - The potent CDK9 inhibitor zotiraciclib, when used in combination was temozolomide, was found to induce clinically meaningful efficacy with a tolerable safety profile in patients with recurrent, high-grade gliomas.

2020 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2021

In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020.

Immunotherapy BND-22 Brings Biond Biologics and Sanofi Together in a Global Licensing Agreement

February 2nd 2021

Biond Biologics Ltd. will join Sanofi in an exclusive worldwide license agreement for the development and commercialization of the novel immunotherapy BND-22.

Dana-Farber Unveils Venture Fund to Aid in Mission to Develop Options for Incurable Cancers

January 29th 2021

January 29, 2021 - Dana-Farber Cancer Institute has announced the launch of its first-ever venture fund, Binney Street Capital, LLC.

Novartis Signs In-Licensing Agreement With BeiGene to Expand Tislelizumab Trials Globally

January 26th 2021

January 26, 2021 - Novartis has signed a strategic collaboration agreement to in-license the PD-1 inhibitor tislelizumab from BeiGene, Ltd, in various markets outside of China.